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INTRODUCTION

Since ancient times, an array of natural and synthetic substances, administered orally or in other fashions, have been used in
attempts to cure mankind's physical and mental afflictions. Individuals possessing special knowledge in the use of physic or
medicines are known as physicians. To this day, the treatment of
patients by their physicians almost invariably includes the prescription of medications. For this reason, the development, production,
and appropriate use of drugs and medicinal substances is more
than just of general interest to doctors; it is at the core of their
profession.
Most practicing physicians have taken the pharmaceutical industry for granted. Physicians have an incomplete understanding
of the research and development that leads to new drugs, and they
are only moderately aware of the regulatory and oversight procedures governing the availability of drugs. The explanation for this
lack of knowledge lies partly with the pharmaceutical industry itself. Until recently, the continuing growth and success of the pharmaceutical industry, both in a scientific and business sense, has
allowed the industry to focus on the clinical attributes of its products, rather than on the complicated fiscal and regulatory issues
involved in making medications accessible to patients. But changes
in the economics and nature of medical practice, together with
federal and state health care legislative initiatives, are sharply altering this state of affairs.
A.

The Thrust of Legislation

A detailed discussion of proposed legislation to govern health
care in the United States is beyond the scope of this Article. Moreover, because there are so many competing proposals before Congress, it is very difficult to predict the final outcome. A cardinal
feature of almost all the legislative initiatives is that they would ensure health insurance for those individuals who, for reasons of affordability, pre-existing medical conditions, employment status, or
personal choice, are not currently covered. Universal access to
health care is a principle that has been widely embraced. It would
be misleading, however, to assume that this praiseworthy motive is
the chief goal of the legislative proposals now being considered. In
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reality, the primary issue is cost, a matter of concern to governments, to industry, and to all others who have been witnessing the
steady and apparently unabating increase in the costs of providing
health care.
Legislation encouraging competitive managed care, which appears to be the most widely promoted approach to the cost problem, has already been preempted in key parts of the United States.
In states such as California, more than fifty percent of patients receive their health care through health maintenance organizations
(HMOs), preferred provider organizations (PPOs), or other structured systems designed to provide efficiency and cost saving in the
delivery of care. Moreover, these organizations already are engaged in fierce competition, providing a foretaste of the price pressures that will be encountered in trying to provide medical care.
This affects all facets of diagnosis and treatment and, very conspicuously, the provision of drugs and other pharmaceutical products.
In some respects, proposed legislation might simply codify
what has already been taking place in the health care marketplace.
It is also fair to say that the debate over health care legislation does
not necessarily follow parochial political lines: much of what the
current Administration is proposing was already coming into existence under previous administrations.
B.

Hypothesis

This Article will examine the effects of changes likely in the
health care picture on the pharmaceutical industry. Specifically,
because this issue is being considered from the perspective of the
physician, we will examine the following hypothesis: namely, that
because the pharmaceutical industry is so integral to all facets of
medical care, major changes in the industry, whether provoked by
legislative or other forces, will markedly affect the professional activities of physicians and medical practices, medical schools, hospitals, insurers, health care organizations, governments, and
especially patients.
The questions posed by this hypothesis will be considered
under several headings: cost issues, fiscal responses by the pharmaceutical industry to health care changes, effects on research, the
impact on patients and their care, and strategies likely to be followed by the pharmaceutical industry in the changing economic
environment of health care.

1994] MEDICINE AND THE PHARMACEUTICAL INDUSTRY
II.

1293

COST ISSUES AND THE PHARMACEUTICAL INDUSTRY

Drug prices are driven downwards by the attempts of health
care providers to minimize cost.1 Quite apart from the formalized
rules that might affect drug purchasing under the proposed health
care legislation, several economic realities already are influencing
drug use and selection.
Because of the availability of multiple alternative products
within several of the major drug categories, including such commonly used groups as antibiotics, antihypertensives, and non-steroidal anti-inflammatories, purchasers often are able to enforce
competitive bidding among pharmaceutical companies wishing to
2
place their products on limited or restricted formularies.
Although competing products indicated for a particular condition
might not be completely identical, they are often judged to be sufficiently similar to allow a formulary to select one or the other
solely on the basis of price. This practice, which is used commonly
by managed care organizations with in-house pharmacies or tightly
I In its April 1993 report, the Boston Consulting Group reviewed in detail the
actions of organized health care plans that have driven down drug prices. The Changing Environment for U.S. Pharmaceuticals (Boston Consulting Group, New York, N.Y.),
Apr. 1993 [hereinafter The ChangingEnvironment]. The report indicates that drug selection is no longer the sole prerogative of the physician, but that insurers, managed
care organizations, pharmacists, major employers, and government agencies have
moved to reduce overall health care costs by using their authority to select drugs for
formulary listings that are less expensive than other available alternatives. Id. at 14.
HMOs have been especially active in driving down the cost of pharmaceuticals. Id. at
17. In addition to restricted formulary availability for expensive drugs, the HMOs
have employed such processes as drug utilization review (in which the cost effectiveness of physician prescribing habits is critically analyzed), generic substitution, and
aggressive negotiations to ensure discounted drug prices from drug manufacturers.
Id.
2 "Formulary" is a formal and widely recognized term that denotes a list of drugs
and pharmaceutical products available for prescription within a hospital, a health
plan, or other system of medical practice. Id. at 18. The entirety of available drug
products in the United states is listed formally in the United States Pharmacopeia,which
is published every few years by the United States Pharmacopeial Convention, Inc.
(Philadelphia).
Obviously, it is not practical for individual institutions or plans to carry the full
array of products, many of which are old and no longer in common use. There are
also multiple redundancies of drug types, and many cases where several manufacturers produce identical or closely similar agents. It is also not practical for pharmacies
to carry the full range of drugs; indeed, the cost of capitalizing an unlimited selection,
as well as the problems of stocking it, requires some degree of selection. See The
ChangingEnvironment, supra note 1, at 17. In most institutions, this selection is made
by a Formulary Committee, which considers and votes upon the drugs to be made
available to prescribing physicians. Administrators have been progressively excluding
physicians from this selection process, replacing them with clinical pharmacists and
managers with high awareness of the costs of drugs as well as drugs' therapeutic
properties.
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controlled external formularies, obviously can also be used by hospitals and major clinics.
A further influence on drug prices is the availability of generic
products that can be marketed more cheaply than the original
branded products once their patent protection has expired.
Although the originating pharmaceutical company continues to
market its product, inevitably it will be forced to offer marked price
reductions to fend off generic competition. It has been claimed
that manufacturers of generic drugs do not always adhere to the
strict standards of manufacture and testing required by the Food
and Drug Administration (FDA), but there has been a growing
trend for the major pharmaceutical houses themselves to enter the
generic drug business.'
A key to the successful marketing of new drug products is to
inform physicians of their existence and to demonstrate how these
innovative drugs might offer clinical advantages over previous
agents. However, to minimize excessive use or awareness of newer
drugs, which typically are more expensive to buy than existing
products, many HMOs restrict pharmaceutical representatives' access to prescribing physicians.4 Indeed, in some staff model
HMOs, where clinical activity occurs physically within properties
controlled by the HMO itself, pharmaceutical representatives often
are denied entry.5 Although there are other sources of information about new drug developments, it is by no means certain that
busy physicians can keep up to date in these areas. Again, in
HMOs or other similar settings, even the educational and scientific
activities of the organization are carefully controlled and monitored by the managers.

3 Elyse Tanouye, Drug Firms Share Risks With Care Givers, WALL ST.J., Dec. 6, 1993,
at B1, B1-B2.
4 See George Anders, Managed Health Care Jeopardizes Outlook for Drug 'Detailers,'
WALL ST. J., Sept. 10, 1993, at Al. This report describes pharmaceutical company
representatives' highly limited access to physicians within HMOs. Id. at A6. Kaiser
Permanente, one of the Unites States' leading organizations, has established thirtytwo rules governing interactions between industry and Kaiser's physicians. Id. These
rules include a prohibition against pharmaceutical representatives even discussing a
drug that has not already been selected for the Kaiser Formulary. Moreover, the rules
also forbid distribution at Kaiser facilities of written materials that do not meet Kaiser
criteria. Drug manufacturers' representatives may meet with Kaiser doctors only after
having prearranged an appointment. Id. Furthermore, in situations where more
than one drug of a particular type is available on the Kaiser formulary, Kaiser administrators themselves will aggressively counter-detail their own physicians to encourage
use of a preferred or cheaper drug. Id.

5 Id.
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A.

An Ethical Dilemma

There is a yet more powerful technique used by administrators
of HMOs and other such organizations to reduce drug costs. In
essence, physicians are promised a monetary bonus if they prescribe drugs in such a way as to save money. Doctors are encouraged to use drug classes intrinsically less expensive than
others, to maximize the use of generic products, and perhaps delay
or even avoid the use of medications for certain conditions. Similarly, physicians practicing in their own offices, but who undertake
to see patients under capitation contracts from HMOs,6 are subject
to withholds: payments of their annual patient care fees are completed only if they document compliance with corporate cost-saving mandates.7
This type of pressure, of course, does not apply only to drug
selection. Other types of therapy, and especially the choice of diagnostic tests, can also be influenced by providing physicians with
personal incentives to care for their patients in ways that are to the
financial advantage of the organization. This can create a serious
conflict for physicians, as shown in Figure 1. Indeed, this problem
directly affects the fundamental basis of the physician's professional relationship with the patient.
In the traditional practice of medicine, doctors have usually
chosen treatments and tests considered to provide the optimal advantage to their patients. This approach at times has been expensive and clearly has created part of the current concern over rising
health care costs, but at least patients have not had to fear that
quality of care is being compromised by forces external to their
6 Many HMOs do not directly hire their own physicians, but instead contract with
outside individual physicians or medical groups to provide physician services. There
are many variations in how these services are funded, but commonly the external
physicians undertake to care for patients for an agreed-upon annual fee negotiated
on a per-patient basis. This method of payment is termed capitation. Physicians then
become responsible for providing full care for the patients allocated to their practices, regardless of the complexity or intensity of these patients' problems. The capitation often includes the primary care physicians' costs in referring patients to
specialists, and additionally includes the costs of diagnostic tests. In general, however,
the cost of hospitalizations are not included within the capitation agreements, and are
carried directly by the HMO. See generally INTERSTUDY, COMPETrrVE EDGE: BIANNUAL
REPORT OF THE MANAGED HEALTH CARE INDUSTRY (1993).
7 See generaUy Home Sweet HMO?, AM. MED. NEWS, Aug. 16 1993, at 3. See also Elizabeth McCaughey, No Exit, NEw REPUBLIC, Feb. 7, 1994, at 21, 21. According to one
source, HMOs such as MetLife, Aetna, and Prudential (though not Cigna) require
physicians to meet targets of reduced tests, referrals, and hospitalizations. Id. at 22. If
such reductions are not met, the physicians may face a withholding of between 1025% of their annual compensation. Id.
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relationship with the doctor. Under the new system, however,
there might be very legitimate reasons for patients to feel apprehensive about being advised and managed by physicians whose personal income partly depends on their willingness to deny or avoid
treatment options on the basis of price. Given this conflict of interest, there must be serious concern about the integrity of the doctor-patient relationship.
Drug selection is a very obvious part of this situation and, as
will be discussed later in this Article, must become an issue of direct involvement by the pharmaceutical industry.
B.

PotentialLegislative Pressures on Drug Costs

The new federal health care legislation currently being proposed would put strong pressures on drug prices through rules
governing the provision of drugs to patients under Medicare.8 The
impact of these rules on the pharmaceutical industry would be substantial, for the Medicare population represents a large proportion
of health care expenditures in the United States. 9 Additionally, because there has been a strong trend for other third party payers to
8 Some of the details envisaged in the legislation proposed by the White House
are listed in Table 1. A more detailed discussion of how some of the downward price
pressures on new drug product introduction might have a deleterious effect on research and development is provided by McCaughey, supra note 7, at 21-22.
9 The Contribution of PharmaceuticalCompanies: What's at Stake for America (Boston
Consulting Group, New York, N.Y.), Sept. 1993 [hereinafter What's at Stake]. The re-

port explains: "On average, the elderly consume four times as much medical care as
do people under 65 because they are ill more often, recover more slowly, and are
more likely to suffer simultaneous illnesses, which complicates treatment." Id. at 11.

1994] MEDICINE AND THE PHARMACEUTICAL INDUSTRY 1297
follow the rules'and standards imposed for Medicare,' ° the new
legislation could have even wider effects. Of course, it is difficult to
predict the final form of legislation in this area, and it is quite likely
that the original proposals will be watered down or even deleted.
It is not the intention of this Article to describe in detail the
proposed Medicare rules, but Table 1 summarizes the benefits and
responsibilities for individual patients in the Medicare prescription-drug benefit program, and also lists the requirements directly
affecting the prices of drugs set by the pharmaceutical industry.
This would not only influence the prices of currently available
drugs, but would also govern the introductory prices of newly developed agents. In turn, this cost pressure would influence the decisions of pharmaceutical companies as to whether to develop and
introduce innovative forms of therapy. This potential limitation on
new developments in treatmentjustifiably could cause anxiety both
to physicians and their patients.
TABLE 1
PROPOSED MEDICARE RULES FOR DRUGS

(i) Medicare Prescription Drug Benefit:
* Beneficiaries Pay 25% Overall
* 20% of Each Prescription
* Limit of $1000 Annually
(ii) Drug Companies Pay 17% Rebate of Average Manufacturer
Price: Rebate Even Higher if:
e Bigger Discounts Already Offered to Non-Governmental
Non-Retail Users
* Prices Rise Faster Than Inflation
* New Drugs Priced Higher Than Existing Comparables
(Council on Breakthrough Drugs)
(iii) Emphasis on Generics
(iv) Prior Approval Required for Non-Cost-Effective Drugs
(v) Physician and Pharmacist "Education"
III.
A.

FISCAL

RESPONSES BY THE PHARMACEUTICAL INDUSTRY

FinancialPressures

Current changes in the health care market, together with possible legislative actions, will potentially decrease pharmaceutical
company income in two ways. First, competitive pressures will
10 See generally Michael A. Palley, Payment Changes Require Integrating Records,
H.ALTHcARE FIN. MGMT., June 1990, at 52.
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force companies to decrease the prices of their branded products.
Second, generic competition can be expected to decrease the market share of several widely used branded drugs. This revenue loss is
already evoking responses as companies develop strategies to preserve profitability by reducing expenditures. Some of the approaches they are using, especially those of interest to practicing
physicians, are listed in Table 2.
TABLE
PHARMACEUTICAL COMPANIES:

A.

2

FISCAL RESPONSES

REDUCE NUMBER OF EMPLOYEES

* Sales Representatives-Middle Management-Research
Personnel
B.

REDUCE PRODUCT PROMOTION

* Journal Advertising (Could Be Fatal for Several Medical
Journals)
" Mailing to Physicians
" Hospital and Society Exhibits
C.

REDUCE EDUCATIONAL SUPPORT

" Grand Rounds and Visiting Professorships (Industry Now
Supports Over 50%)
" Scientific Programs and Symposia of Major Medical
Societies
" Donations and Corporate Memberships of Professional
Societies
D.

REDUCE RESEARCH

* Immediate Cash Savings Enhance Profitability and Protect Stock Prices
Many companies have already responded to the ongoing financial pressures by reducing their workforces. Industry wide,
30,000 jobs were cut in 1993.11 Although this has occurred at all
levels throughout the industry, it has become evident to practicing
clinicians that there has already been a perceptible reduction in
the number of pharmaceutical sales representatives. To some extent, this is not an adverse trend-except, obviously, for the unfortunate individuals who have lost their jobs-because there has
been a strong feeling among physicians that they have been besieged by an excessive number of representatives. During the past
ten to twelve years, most companies substantially increased the size

11 American DrugFirms: Kicking the Habit, THE ECONOMIST, Dec. 25, 1993, at 90, 90.
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of their sales forces, in some instances two- or three-fold. 1 2 Thus,
the current trend to decrease the number of representatives by ten
to thirty percent could be regarded as an appropriate rationalization of the sales effort.
B.

Promotion and Education

Some of the cost reduction strategies being undertaken by the
pharmaceutical industry could have clearly negative impacts on
medical, educational, and scientific activities. Advertising in medical journals, which during the past several months has been reduced by at least thirty percent, 13 has long been a financial
mainstay for many leading peer-reviewed scholarly journals of
medicine. In essence, drug advertising provides a subsidy for these
publications, and the survival of the less economically robust journals, including some with strong scientific value, might be jeopardized. Another form of pharmaceutical support for medicine comes
through product-related exhibits, often at a substantial fee, at hospital meetings or at clinical societies' scientific sessions. A reduction in this type of promotion also will adversely affect educational
activities for practicing and academic physicians.
A reduction in drug companies' direct support for education
can also be expected. At present, industry directly sponsors at least
fifty percent of grand rounds1 4 and visiting professor programs at
hospitals and medical academic institutions. 5 Indeed, for many
community hospitals the expenses and honoraria required to sup12 See C. Marshall Paul, Time to Cut Back on Detailing, MED. MARKETING & MEDIA,
Oct. 1993, at 94, 94 ("There was a 50 percent increase in the number of pharmaceutical representatives during the 80's .... Increases in salesforce size continued into the
90's at the rate of 12 percent per year.... .") (quoting Larry Levin, President of ScottLevin Associates, Newton, Pa.).
13 See The PERQ Report (PERQ Research Corporation, Wilton, Conn.), Spring 1994.
14 The term "grand rounds" is generally used within the medical profession to
describe a formal educational program. Typically, grand rounds are held weekly, and
are the most important lecture or teaching event for medical departments. Historically, grand rounds were practical demonstrations and discussions of interesting or
instructive patient problems, but more recently grand rounds have become predominantly didactic sessions. In many institutions the grand round is a requirement, or at
least there is a strong expectation that all affiliated physicians attend. An interesting
history of grand rounds has recently been published. See John D. Stobo, Medical
Grand Rounds at Hopkins, 261 JAMA 3164 (1989).
15 Formal documentation of this 50% figure is not easily obtained. In the author's
personal experience, however, as a lecturer and audience member at several hundred
grand rounds during the past 20 years at medical schools, academic medical centers,
and community hospitals, it appears that markedly in excess of 50% of these programs are provided by direct pharmaceutical industry sponsorship or through educational grants provided by the industry.
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port these programs almost invariably are provided by industry
sources. Just as importantly, scientific programs and symposia at
major medical meetings frequently are sustained by the pharmaceutical industry. Even though this support often is done with the
intention of providing visibility for specific products, the majority
of pharmaceutical companies have been willing to provide full financial backing for programs that are predominantly scientific and
educational in their content. There has been a perceptible drop
off in the number of sponsored symposia at major medical meetings during the last year. In addition, pharmaceutical companies
often serve as corporate members of major medical professional
societies; their gifts, although relatively small in the context of the
overall financial position of industry, nevertheless are of great importance to the viability of several scientific professional societies.

IV.

EFTECTs ON RESEARCH

The pharmaceutical industry has made a large financial commitment to research, and a reduction in research activity-even if
temporary-has the immediate effect of conserving drug companies' cash resources. In turn, this enhances the companies' profitability and, at least in the short-term, helps protect stock prices.
This is potentially a dangerous strategy, however, with negative implications both for the industry and for the whole medical enterprise. Maintaining adequate research in the face of changes in the
health care system is a critical issue for academic and clinical
medicine, and the nation as a whole.
A.

The High Cost of Research

There has been a dramatic increase in the cost of bringing a
drug to market during the past several years. The total cost of
bringing a drug to market in 1976 was $54 million. 16 It was $125
million in 1984,17 $231 million in 1987,18 and $350 million by the
early 1990s.19 The drug development pyramid has an enormous
base; to produce one drug for the marketplace, 5000 molecules
with clinical potential must be conceived, synthesized, and evaluated by the industry's scientists. 2 Of these, about 500 are found to
be worthy of examining in organ preparations; and, in turn, 250
16 Joseph A. DiMasi et al., Cost of Innovation in the PharmaceuticalIndustry, 10 J.
HEALTH ECON. 107, 114 (1991).
17 Id.
18 The ChangingEnvironment, supra note 1, at 40.
19 Id.
20 See generally Sol I. Rafjer, Perspective of the PharmaceuticalIndustry on the Development
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are tested in animals. 1 The huge pre-clinical development process
ultimately is able to reduce the original 5000 molecules to 5, or
0.1% of the original quantity, that are eligible for evaluation in
humans.22 Even at this advanced stage, only one of 23these five drug
candidates will ultimately be placed on the market.
To some extent, it is possible to attribute this enormous commitment, and the resultant high cost, to regulatory requirements
promulgated by the FDA. But it is also likely that with so many
drugs already available, it is becoming progressively more difficult
to produce new products that genuinely represent much-needed
progress. At the same time, concerns about liability have forced
the industry to be especially diligent in evaluating all possible safety
issues with their new products, including expensive long-term
surveillance.
B.

Research Pressures: PharmaceuticalCompany Perspective

It is difficult to summarize the ways in which pharmaceutical
companies are dealing with research issues in the current environment, for it is still too early to focus a clear picture of the strategies
being employed to enhance the efficiency of research activities. At
present, the pharmaceutical companies appear to spend more of
their income on research than any other major industry. It is estimated that approximately one-sixth of industry revenues are directly reinvested into research activities." Because of the current
price pressures on drugs, as well as likely limitations on introductory prices of new products, the industry inevitably will be conservative in deciding which new products appear worthy of research
investment.
At present, most companies are continuing to support prodof New Drugsfor Heart Failure, 22 J. AM. C.
Stake, supra note 9, at 92.
21 What's at Stake, supra note 9, at 92.
22 Id.

CARDIOLOGY

198A-200A (1993); What's at

23 See OFFICE OF TECHNOLOGY ASSESSMENT, PHARMACEUTICAL R&D: COSTS, RISKS,

76 (1993) (explaining that "[u]timately . . . only 20 of the 100 [new
drug] candidates jump all the hurdles and reach the market").
24 See The ChangingEnvironment, supra note 1, at 35 (pointing out that research and
development spending constituted 17% of pharmaceutical sales during the 1980s). A
review of spending on research and development by the pharmaceutical industry in
the United States has indicated an almost 10-fold increase between 1968 and 1992
based on data provided by the Pharmaceutical Manufacturers Association. Id. According to the investigation performed by the Boston Consulting Group, research
and development as a percent of gross sales is approximately 17% at the present time.
Id. The Boston Group also points out that the electronics industry, by comparison,
invests less than six percent of its sales in research and development. Id.
AND REwARDs
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ucts already on the market, or approaching release, with prudent
clinical trials. There is less enthusiasm, however, for truly new
products that might demand very expensive research and development budgets. One option for the major pharmaceutical companies is to acquire highly promising products by obtaining licenses
to market the products from smaller innovative companies. An extension of this approach, also in evidence, is for the major companies to actually acquire smaller companies that appear to have
promising drug pipelines.
These short-term strategies do not fully address one fundamental research dilemma that the industry will soon face. Quite
independent of economic or legislative factors, basic medical science, especially molecular biology, has provided a new understanding of the genetic basis of disease. In turn, highly specific products
tailored to selectively treat diseases resulting from abnormal or undesirable genetic characteristics can now be developed. It is likely
that the cost of this type of research will be high, and it is also
probable that the prices of these types of products will also be
greater than those being charged for current state-of-the-art drugs.
Clearly, this creates a situation of high risk for the pharmaceutical
industry.
Other aspects of pharmaceutical products, however, are unchanging. For the most part, drugs primarily are intellectual property. Their worth is linked to the research that has created them;
they have relatively little intrinsic material value. Thus, once a
drug is no longer innovative, or its patent has expired, the drug has
relatively little commercial value to its manufacturer. The industry
has no choice other than to continue with research activities, for
without creative work there can be no new products; and without
new products, the pharmaceutical industry cannot exist in any
meaningful fashion.
C.

Research Pressures: Academic Perspective

A large part of the pharmaceutical industry's research and development investments is spent at academic centers, chiefly medical schools. Figure 2 illustrates that research and development
expenditures by the major pharmaceutical companies already outstrips the contributions to medical research of the National Institutes of Health (NIH). Although it is difficult to accurately
quantify the drug industry's specific funding of projects at academic medical centers, it appears reasonable to estimate that as
much as fifty percent of research funding within clinical depart-
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ments at medical schools originates with industry.25
To a substantial extent much of the industry's investment in
medical schools is in support of projects, either basic or clinical,
related to the development of pharmaceutical products. But from
the perspective of the academic institution, this expenditure by the
pharmaceutical industry is of far greater importance than could be
envisaged simply by a routine contractual relationship. Much of
this funding, although project directed, supports the academic careers of faculty members and is used to subsidize research activities
that may be unrelated to the drug projects. Drug trials, for example, are often performed by clinical departments as a means of attracting revenues that sustain basic science laboratories, provide
salaries for research fellows who are gaining experience in clinical
or basic research, and augment other sources of research support.
To some extent, the majority of academic physicians depend on
support from industry. In turn, this source of funding plays a

25 Although firm data are not readily available, it is author's experience that funding for general research activities at clinical departments in the author's own academic institution is derived substantially from industry sources. Personal
communications with senior faculty at other comparable institutions suggest a similar
state of affairs. A careful survey of the sources of research funding for academic
clinical work would be of much interest to industry, health care observers, and the
institutions themselves.
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meaningful role in maintaining the research, teaching, and clinical
trinity that underlies the careers of most academic clinicians.
Two trends now threaten to undermine this important relationship. First, the general reduction in research expenditure by
the pharmaceutical industry will inevitably result in fewer dollars
being invested in clinical trial activities. Second, in an environment of rigorous cost constraints, private research centers and
medical practices can often underbid academic centers and preferentially receive contracts from the industry or its contract research
organizations, thus squeezing out the major academic institutions.
The implications of these trends not only portend adverse effects on academic institutions, but have national implications as
well. New developments in the basic sciences, molecular biology,
applied biology, and human physiology are all seriously threatened
by the diminishing income from industrial sources. Despite the
important contributions of the NIH and other governmental or
public sources of research funding, the pharmaceutical industry
has gradually assumed a key role in providing support for advances
in medical care-even those that are not directly related to drug
development.
V.

A.

IMPACT ON PATIENTS

Beneficial Effects of Changes in the Health Care System

As discussed earlier, patients can derive three general benefits
from the proposed legislation. First is the promise of universal access to health care, making such care available to all regardless of
financial or employment status. Second is the promise that this
universal health care access cannot be limited by previous or ongoing medical conditions. And third, despite expecting individuals
to carry a partial financial responsibility for their care, there are
limits on the overall burden that could fall to any one individual or
family. Clearly, these commitments are all praiseworthy, but they
comprise only a small part of the impact and motivation for the
overall changes that are envisaged.
B.

Negative Effects from the Patient'sPerspective

Because the relationship between the doctor and patient traditionally has been the cornerstone of medical care, some of the issues affecting physicians, detailed earlier, would have similarly
negative connotations for patients.
The issue of drug availability, although quantitatively a relatively small proportion of overall health care cost issues, lends itself
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to analysis and is also of obvious relevance to the interests of the
pharmaceutical industry. One obvious cost-saving measure is to enforce or encourage the use of less expensive drugs. In turn, from
the patient's perspective, this could mean receiving a less-than-optimal treatment choice. This cost-saving can be achieved formally or
informally within individual plans, or it can be governed by major
central forces.
The proposed rules for Medicare have already been discussed,
but major commercial participants in this process already exist.
For example, Medco is a corporation providing pharmaceutical
services to a large number of health plans. In addition to being a
major wholesaler of drugs, Medco advises health plan organizations on their formulary2 6 selections, and provides-typically at discounted prices-an array of pharmaceutical products to the health
plan participants. To aid in acquiescence with their recommended
drugs, Medco employs a large number of pharmacists whose job is
to continually call and persuade-or jawbone-prescribing physicians to conform with the Medco range of products. A fascinating
complication recently has arisen because of Medco's acquisition by
one of the nation's largest pharmaceutical corporations, the Merck
Company, for six billion dollars.2 7 Clearly this enormous investment provides Merck with an opportunity to promote its products,
especially when they are closely similar to brands offered by
competitors.
Another way in which HMOs or other plans limit patient access to expensive drugs is by the bottleneck technique. Conditions
that require relatively expensive drugs-for example cholesterol
abnormalities or Alzheimer's Disease-are often directed to low ca26 See supra note 2 for an explanation of institutional formularies and the manner
in which drug products are made available to prescribing physicians.
27 Michael Waldholz & George Anders, Merck to PurchaseMedco in $6 Billion Transaction, WALL ST. J.,July 29, 1993, at A3. This highly unusual purchase by Merck & Co.,
a pharmaceutical company, indicates that the alliance with Medco, America's largest
marketer of discount prescription drugs, would certainly shake up the pharmaceutical
industry. According to Waldholz & Anders, Merck's purchase
is certain to intensify price competition among drug makers, which in
the past year has pushed down drug company revenues, profit growth,
and share prices.
...
Medco manages the prescription-drug benefit plans for many
corporate and government employees through a discount mail-order
business and retail pharmacy insurance program. Recently, Medco has
become particularly effective in wringing sharp discounts from drug
makers and signing up corporate customers by passing on the price
savings.
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pacity specialty clinics. Only the doctors assigned to these clinics
have the authority to prescribe the appropriate drugs. Moreover,
other doctors wishing to refer patients to these clinics must first
document that they have exhausted all the more simple remedies
before their patients can become eligible for the "specialist" care.
Inevitably, the referring physician's frustration, and the long, inconvenient delays that patients must endure while waiting for an
appointment to become available, effectively limit utilization of the
more expensive modern treatments.
A second recent issue attracting much publicity was the decision of the Kaiser HMO not to include the recently marketed agent
tacrine (Cognex) in its formulary.2 8 Cognex is the first drug approved by the FDA for the treatment of patients with Alzheimer's
disease. 29 In its approval process, which is acknowledged to be the
most meticulous and rigorous in the world, the FDA acknowledged
that Cognex had a favorable efficacy and safety profile. Cognex
cannot prevent the ongoing deterioration associated with
Alzheimer's disease, but through both psychometric testing and
physician assessment, Cognex clearly improved intellectual function. Despite the FDA approval and recognition of potential beneficial effects of this agent, the Kaiser formulary decided that the
benefits of treating its patients with this drug were not worth the
price of three dollars per day.3 °
28 See supra note 2 for a definition of formulary.
29 See 55 F-D-C REPORS-THE PINK SHEET (Chevy Chase, Md.) Sept. 13, 1993:

Warner-Lambert's Cognex (tacrine) was approved Sept. 9 by FDA for
the treatment of patients with 'mild to moderate dementia of the
Alzheimer's type.' Cognex is the first drug approved specifically to treat
symptoms of Alzheimer's, which the FDA estimates affects four mil [lion]
people in the U.S. and results in the deaths of 100,000 people annually.
Id.
30 Harvey Schwartz, HMO's-Another Road Block for Alzheimer's Drug, WALL ST. J.,
Oct. 5, 1993 at A16. This report describes the approval by the FDA of the drug for
Alzheimer's disease, Cognex, and indicates that fee-for-service physicians "no doubt
will write prescriptions for patients they think may be helped by Cognex." Id. But
Schwartz points out that two major HMOs, the Northern California Kaiser
Permanente and the Group Health Cooperative of Puget Sound, have shown great
reluctance to make the drug available to their patients. Id. Northern California Kaiser decided to ban Cognex from its formulary, and has planned to issue an information sheet explaining to its members why it is not making this drug available. Id. The
Puget Sound Group has made a similar decision, but since it is a cooperative that is
ultimately governed by its patient members, this decision may well be overturned. Id.
Schwartz also points out that this drug would cost between $1300 to $1500 per year
for each patient. Id. Moreover, the article discusses the economic basis for Kaiser's
decision, indicating that the addition of any new form of treatment must be offset by
an accompanying saving in another area if the HMO is to maintain a constant expenditure on its services. Id.
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Regardless of the scientific and clinical aspects of this issue,
Kaiser's decision to withhold access to Cognex, despite the FDA's
approval, must inevitably provoke concern and a reaction by its patients. Indeed, Kaiser may well be forced to modify its decision,
but the impact of this important precedent remains. This situation
leads to some interesting further questions.
For example, will other HMO plans make the opposite decision and add Cognex to their formularies, thus demonstrating in a
highly competitive marketplace that their plans offer a greater
depth of care and compassion than Kaiser's plan? Or, will the
competing HMOs take a more passive stance and follow the lead of
the Kaiser formulary in denying patients access to treatment with
Cognex?
A further issue, albeit not directly drug related, recently arose
in dramatic fashion when the Health Net HMO in California withheld therapy from a woman with breast cancer. 1 The patient died
after the HMO had decided not to provide bone marrow treatment
for her advanced disease.3 2 In the Riverside (California) Superior
Court, ajury awarded the patient's family $12.1 million in compensatory damages. 3 3 But of even greater weight, the jury then ordered the HMO to pay an additional seventy-seven million dollars
in punitive damages.3 4
The most interesting aspect of this case was not the argument
over the merits of the treatment, or even the legal obligations of
the HMO or insurer. Rather, the case was characterized by the
outrage of the jury upon learning that Health Net HMO, while denying treatment to the dying woman, provided their corporate exIn an interesting argument, Schwartz points out that the majority of patients
within an HMO, at any given time, are in good health; only a small minority have
illnesses that would stimulate them to fight for an upgrade in their treatment. Id.
Thus, while the majority of patients are disinterested and unorganized,
the staff [in the typical HMO] usually has potent incentives to economize ....

It is normal in HMOs for primary care physicians to have

quotas as to how many tests they may order, how many outside consultants they may refer to, and how many prescriptions they may write.
Moreover, bonuses are frequently offered to doctors who cut extra costs
appreciably below their quota levels.
Id.
Parenthetically, it is possible that the drug could delay the need for nursing
home placement-at approximately $30,000 per year-for some of these patients. Of
course, Kaiser usually is required to pay for the drugs, but not for nursing homes.
31 Tom Gorman, Jury Adds $77 Million Against HMO That Denied Coverage, L.A.
TIMES, Dec. 29, 1993, at Al.
32
33
34

Id. at A2-A3.
Id. at Al.
Id.
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ecutives with financial incentives and bonuses for refusing to
authorize expensive procedures and treatments. 3 5 Although this is
a relatively extreme example, it indicates that the general public,
most of whom sooner or later become patients, will not tolerate
health care plans whose financial success or profitability appears to
be predicated upon denying contemporary standards of treatment.
The availability of modern drugs, which sometimes provides moderate advantages over older products but for a somewhat greater
price, readily falls into this area.
In support of this trend, some articles 36 have reported results
of questioning patients on those aspects of medical care that the
patients would be least willing to sacrifice in any planned changes
in the health care system. Out of several choices, access to new
drugs and technology was listed as the most important attribute to
preserve.
Access to health care regardless of age was second on
the list, and third, the freedom of patients to choose their doctors.3" Other choices, including malpractice limits or mandatory
second opinions, were ranked lower.3"
Although the top three selections are probably not really surprising, the results of this survey seem to send a strong message
that patients, perhaps even more than physicians themselves, do
not appear willing to accept compromises in the quality of their
treatment with state-of-the-art pharmaceutical products and other
therapeutic techniques.
C.

Cost-Effectiveness and Outcomes Research

Health care economists are always careful to differentiate between the terms "cost saving" and "cost effectiveness." Cost saving
generally implies a short-term strategy in which goods or services
are acquired for the cheapest possible price, often without regard
to long-term economic consequences and therapeutic results.40 In
35 Id. at A3.
36

See, e.g., Health Care Crisis: Satisfaction and Sacrifice, MED.

BENEFITs,

Aug. 30, 1992,

at 7.
Id. at 6.
Id.
39 Id.
40 Robert M. Goldberg, PharmaceuticalPrice Controls: Saving Money Today or Lives
Tomorrow?, IPI POLICY REPORT No. 123 (Institute for Policy Innovation, Lewisville,
Tex.), Sept. 1993 (Introduction). This article makes the argument that pharmaceutical products, even when relatively expensive, are net savers of health care dollars because they treat conditions that would otherwise require expensive surgery. Id. The
report also provides data indicating that drug therapy for coronary artery disease costs
approximately $1000 per year compared with $41,000 for bypass surgery; drug therapy for ulcers costs $900 compared with $25,000 for surgery; and drug therapy for
37
38

1994] MEDICINE AD THE PHARMACEUTICAL INDUSTRY

1309

turn, the choice of an inexpensive cost-saving drug that fails to prevent a serious medical complication, which thereafter results in an
expensive hospitalization, would be less cost-effective than a more
expensive product that successfully achieves its goals.
Recently, the State of New Hampshire issued restrictive pharmaceutical guidelines for its Medicaid program: patients were
each limited to a maximum of three drugs.4 1 This cost-saving measure backfired. Nursing home admissions, which are a far more
expensive proposition than drug therapy, rose in these patients,
42
and almost certainly increased overall costs.
Heart failure, which is the most common reason for hospital
admissions in the elderly, provides a further illustration of the
drawbacks of cost-saving initiatives. Effective outpatient treatment
for heart failure usually requires the use of three separate drugs (a
diuretic,4 3 an ACE inhibitor,44 and digitalis4 5 ), quite apart from the
drugs needed to manage other concomitant problems. The combined cost of heart failure drug treatment is less than two dollars a
day. The cost in 1989 of a typical hospitalization for heart failure,
often necessitated by inadequate outpatient drug treatment, was
$6,373.46 Other research has shown that patients who reliably take
their medications have significantly reduced needs for physician
and laboratory services.4 7 It is not difficult to argue that drug therdepression costs $5000 per year compared with $73,000 to institutionalize an individual. Id. at 2. The basis for these numbers is not clearly explained, but it is possible
that-if anything-the estimate of drug costs may actually be excessive. Unfortunately, without specific examples of drugs being given, it is not possible to form an
accurate assessment. Nevertheless, the article appears, overall, to argue convincingly
that drug therapy is a highly cost-effective alternative to other treatment modalities.
41 What's at Stake, supra note 9, at 145.
42 Stephen B. Soumerai, et al., Effects of Medicaid Drug-Payment Limits on Admission to
Hospitals and Nursing Homes, 325 NEw ENG. J. MED. 1072, 1074 (1991).
43 Diuretics are drugs that have their primary actions within the kidney and facilitate elimination of sodium and water from the body.
44 ACE (angiotensin converting enzyme) inhibitors are drugs that work on the
renin angiotensin hormone system, specifically blocking formation of angiotensin II.
Because this hormone is responsible both for raising blood pressure and for increasing the resistance against which the heart has to pump, the ACE inhibitors are commonly prescribed for the treatment of hypertension (high blood pressure) and
congestive heart failure.
45 Digitalis is an ancient medicinal product that is derived from the purple fox
glove. Originally, the drug was administered as a powdered form of the plant leaf, but
now is administered as tablets of the derivative, digoxin. This substance has a stimulatory effect on the contraction of the heart, and thus helps the heart to perform more
effectively in patients who have congestive heart failure and certain other cardiac
abnormalities.
46 Rajfer, supra note 20.
47 David A. Sclar et al., Utility of a TransdermalDelivery System for Antihypertensive Therapy, Part 1., Am. J. MED., July 18, 1993, IA-50S, 1A-5053S (Supp.).
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apy appears to be the most cost-effective approach to overall medical care.
Outcomes research 48 has become the vogue expression to describe the evaluations of treatment, typically with pharmaceutical
products, in terms of the treatment's ability to provide benefits that
go beyond the obvious immediate pharmacologic actions of the
drug. Of course, outcomes can be measured in medical and
human terms as well as in economic or resources terms. But issues
that so obviously mix human and economic variables often cannot
be resolved satisfactorily, and can create conflicts between patients
and health care providers.
One illustration is the controversy over performing surgery for
prostatic cancer in men over a certain age. It is possible that this
procedure, even if curative, may not be justified in terms of the
cost of surgery, hospitalization, and rehabilitation because many of
the men afflicted with this condition would, in any case, die of
some other cause before their cancer proved fatal. Indeed, the argument can go one step further: if it is unlikely that cancer treatment for a man of a certain age would be offered, why even
perform the examination or tests that might reveal its existence?
A similar situation could easily arise in the context of drug
therapy. For example, effective treatment of cardiovascular risk
factors in young people could markedly delay serious events. But
for people already in old age, especially if other medical conditions
are already present, the benefits of treatment-even if proven sta49
tistically-are clearly more modest in terms of prolonging life.
48 Bryan R. Luce & Kit Simpson, Methods of Cost Effectiveness Analysis: Areas of Consensus and Debate, PHARM. MANUF. ASS'N (Battelle Med. Tech. Assessment & Policy Res.
Ctr., Washington, D.C.), Apr. 22, 1993, at iv. In general, evaluations of cost-effectiveness in medicine remain an area of controversy. Extreme examples are easily understood. An inexpensive vaccination of a child that prevents serious or fatal illnesses
later in life clearly is an example of a highly cost-effective maneuver. On the other
hand, spending tens of thousands of dollars on major diagnostic tests and procedures
to minimally palliate or delay the inevitable and imminent outcome of a terminal
illness would generally be considered not cost-effective. The difficulty in defining
cost-effectiveness, however, lies in the more common intermediate situations. Can
length of life be translated into dollar terms? What is a reasonable price to pay per
year of life saved? How can we truly measure quality of life? How can we measure the
negative emotional effects of treatment, or non-treatment, on sick patients and on
their relatives and friends? If pursued to their logical conclusion, these issues-and
many others like them-quickly go beyond the realm of medicine and economics,
and involve religion, philosophy, ethics, personal beliefs, and societal values. Outcomes research tries to simplify this highly complex dilemma by looking for more
simple solutions. Some of these approaches are discussed in the text.
49 R. D. Abbott & D. McGee, The Probability ofDeveloping Certain CardiovascularDisease in Eight Years at Specified Values of Some Characteristics,in THE FRAMINcHAM STUDY'
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A recent controversy in the medical literature has focused on a
Coronary Heart Disease Policy Model proposed by public health
physicians to guide the cost-effective selection of drugs to prevent
heart disease." ° Disagreements over the interpretations and validity of clinical trials, availability of long-term data for some drugs but
not for others, conflicting assumptions about the negative as well as
the positive attributes of drugs, contentious statistical questions,
and difficulties in measuring patient quality of life, all contributed
51
to angry but inconclusive published exchanges among experts.
Rightly or wrongly, the reader was left with the concern that scientific method was being compromised by economic and political
issues.
These types of questions, naturally seen by the patient in a different fashion from that of the health plan administrator, are likely
to be confronted with increasing frequency in the area of drug
products. The Cognex issue, discussed earlier, is an example of
this phenomenon. Outcomes research, like any other research,
provides data that must then be analyzed and interpreted. The
critical question thus arises: how will the lay patient be able to follow the complexities of these issues and be informed adequately
about the rationale for being offered certain forms of treatment
but not others?
D.

The Concept of Prevention
There are few ideas more beguiling than preventive medicine.

AN EPIDEMIOLOGICAL INVESTIGATION OF CARDIOVASCULAR DISEASE (W.

B. Kannel et al.

eds., 1987).
50 See Jonathan T. Edelson et al., Long-Term Cost-Effectiveness of Various Initial
Monotherapiesfor Mild to Moderate Hypertension, 263 JAMA 407, 408-11 (1990) (describing the Coronary Heart Disease Policy Model).
51 Compare Norman M. Kaplan, Cost-Effectiveness of Antihypertensive Drugs: Fact or
Fancy?, 4 Am.J. HYPERTENSION 478 (1991) with Lee Goldman & Milton C. Weinstein,
Reply to Kaplan, 5 AM. J. HYPERTENSION 666 (1992).
As discussed in the text, there are many issues in this type of outcomes research
that readily lend themselves to controversy. Indeed, the editorial by Dr. Kaplan,
which criticized the original outcomes article by Edelson et al. (see supranote 50) and
provoked the angry secondary response by Goldman et al., used the term "so-called
experts" to describe the authors of the original article. See Kaplan, supra, at 478 ("We

must counter these misleading figures whenever they appear from the so-called experts in cost-effectiveness."). Dr. Kaplan's point was not to diminish the integrity or
scholarly standing of the authors, but to argue that outcomes research is still so speculative, lacking in guidelines, and poorly supported by credible data, that it is difficult

for any authors-regardless of their stature or academic position-to be truly regarded as experts. These disagreements help to highlight the frustrations of many
participants in the health care debate at the lack of consistently effective methods of
outcomes research.
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Vaccination is an excellent example of how a relatively simple and
inexpensive procedure at an early age can prevent serious and lifethreatening diseases later on. Preventive medicine has taken on
broader meanings during the past few years. Persuading patients
to stop smoking, for example, is an obvious means of reducing patients' risks of developing such conditions as lung cancer or heart
disease.
Other strategies are less obvious in their benefits, and apparently more difficult to achieve. For example, losing weight, reducing the amount of fat or sodium in the diet, and increasing
physical activity are strategies thought to be of benefit in helping to
control such conditions as high blood pressure or cholesterol abnormalities.5 2 One of the main rationales for the HMOs themselves-indeed, the use of the words "health maintenance" in their
name-has been the encouragement of such strategies.
It could be argued that these lifestyle modifications help to
give patients themselves an active part in being responsible for
their own health. This attractive concept, when successful, is obviously pleasing to all concerned. In many instances, for reasons that
are not always clear, and which usually do not indicate a lack of
interest or commitment on the part of the patient, these lifestyle
strategies are ineffective, and it becomes necessary for the physician to prescribe appropriate drugs to control such problems as
high blood pressure or high cholesterol. Clearly these forms of
treatment can at times be expensive, and it is noteworthy that governmental and other committees5 3 have been at work to marshall
52 Joint National Committee on Detection, Evaluation, and Treatment of High
Blood Pressure, The Fifth Report of the Joint National Committee on Detection, Evaluation,
and Treatment of High Blood Pressure (JNC V), 153 ARCHIVES INTERNAL MED. 154, 162-64
(1993).
53 See National High Blood Pressure Education Program Working Group, National
High Blood PressureEducation Program Working Group Report on Primary Prevention of Hypertension, 153 ARCHIVEs INTERNAL MED. 186 (1993) (providing example of the work
product of a committee formed to study modes of treatment in the medical profession). This Committee had been established under the aegis of the National Heart,
Lung, and Blood Institute, which is one of the National Institutes of Health (NIH).
The Committee is made up of experts, chiefly from the academic world, in the fields
of cardiovascular medicine, hypertension, and lipid disorders, who have been selected
by NIH officials to participate in generating guidelines and recommendations. Such
committees are generally respected, especially as they tend to be composed of scholars enjoying high stature in their fields of study. On the other hand, these committees also are vulnerable to criticism, especially if the members are selected on the
basis of their known commitments to certain points of view. Are the NIH officials,
perhaps analogous to a trial lawyer, carefully selecting only those experts who will
help them to make their case? In the case of hypertension recommendations, an
editorial indeed has made such an assertion. See Michael A. Weber &John H. Laragh,
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arguments in support of broad lifestyle modifications for large segments of the population.
Although attempting to modify lifestyle habits is a desirable
goal, there is concern that these approaches, which have not yet
been subjected to measurements of long-term outcomes, are being
proposed more for their potential to save money for health plans,
and not for an individual patient's health benefits.5 4 It is quite
likely, however, especially for chronic conditions such as hypertension, that pharmacologic treatment is more effective than life-style
modifications, 5 and such treatment might even be less expensive.
But whereas drug purchases usually are undertaken by the health
plan, the expenses of dietary modifications and exercise programs
are at least partly borne by the patient. Thus, preventive medicine
can have the effect of transferring costs from the organization to its
subscribers.
Preventive medicine, whether based on pharmaceutical agents
or life-style modifications, is influenced by another hard reality.
Vigorous competition among managed care plans, apart from putting pressure on premium costs, causes about twenty-five percent
of patients to switch from one HMO to another every year. Despite
their propaganda to the contrary, there is relatively little incentive
for health plans to invest in true long-term prevention. In essence,
each of the plans is playing a game of medical musical chairs, hoping that the patient who has a disabling stroke will have it while
enrolled with one of its competitors.
E.

Who Sets the Rules?

Until recently the choice of drugs or other forms of treatment
was made by physicians on a case by case basis for each of their
patients. Unless these treatments were potentially dangerous, or
perhaps so new as to be yet incompletely understood except by
experts, drug selection would be made by doctors on the basis of
their own knowledge and experience. The influences of restricted
formularies, cost cutting incentives, and jawboning techniques by
external pharmaceutical consultants have all markedly altered this
freedom of selection.
Who protects the patient in this setting and ensures that adeHypertension: Steps Forwardand Steps Backward, 153 ARCHIVES INTERNAL MED. 149, 15152 (1993).
54 Weber & Laragh, supra note 53, at 149-51.
55 SeeJames D. Neaton et al., Treatment of Mild Hypertension Study: FinalResults, 270
JAMA 713 (1993).
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quate state-of-the-art treatment is still being provided? It is becoming more difficult to apply so-called community standards of care
in a rapidly changing system, and the major professional medical
societies-although recognizing a need to issue guidelines-are
not always sufficiently organized or widely based to assume the authority of true leadership in setting standards of care.
The proposed federal health care legislation envisages that
certain standards and practices will be conceived and regulated
centrally. One recent experience, with interesting implications for
the use of drugs, is currently stimulating intense debate in the field
of hypertension. Hypertension is very prevalent in the United
States, and the NIH (Department of Health and Human Services)
helped establish a committee under its aegis referred to as the
Joint National Committee (JNC) on the Detection, Evaluation, and
Treatment of High Blood Pressure. The JNC, composed of external experts carefully selected by officials of the NIH, has issued
therapeutic recommendations on hypertension to the medical
community at four-year intervals during the past twenty years.5 6
The recommendations of 1988 (referred to asJNC IV because
it was the fourth report of the Committee) included four groups of
drugs: beta blockers, diuretics, ACE inhibitors, and calcium channel blockers. At that time, beta blockers and diuretics were already
well established for the treatment of hypertension, but the ACE
inhibitors and calcium channel blockers were newer classes of
agents then becoming recognized as effective newer alternatives.
Subsequently, these newer classes have started to dominate the
field of hypertension treatment.
To the surprise of most experts in hypertension, the JNC V
Report (in 1993), although still advising use of the same four drug
classes, actually labeled the older groups-the beta blockers and
diuretics-as "preferred."5 7 The Committee, which clearly had
highly contentious internal deliberations, argued that only the
older drug classes have thus far had the opportunity of demonstrating beneficial impacts on morbidity and mortality during longterm follow-up. 5" The newer drugs, the Committee argued,'
although potentially as good as the older agents-or perhaps even
56 The Joint National Committee's most recent report was published in 1993. See
Weber & Laragh, supra note 53, at 149-51 (providing references to previous reports by
the same committee that extend back twenty years).
57 SeeJoint National Committee, supra note 52, at 183.
58 See id. at 178 (pointing out that only beta-blockers and diuretics have been used
in trials that showed a reduction mortality and cardiovascular morbidity).
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better-have not yet been tested in the same way, and thus cannot
yet be granted "preferred" status.
Not surprisingly, the JNC recommendation was greeted with
dismay and sharp criticism.5 9 This criticism stemmed from several
well-known facts. First, the benefits demonstrated for the older
drugs still are well short of ideal. Moreover, the newer drug classes,
although admittedly not yet fully proven in the hypertension arena,
have produced cardiovascular benefits that, by reasonable extrapolation, should make them the treatment of choice for hypertension. Finally, the JNC Report, which strongly stressed the needs for
cost containment, appeared to have been strongly influenced in its
therapeutic recommendations by the fact that its "preferred" drugs
are older and cheaper than the newer alternatives.
Ironically, as discussed earlier, drugs that cost less to acquire
may not be truly cost-effective. Diuretics, for example, while inexpensive in their generic form, cause unwanted changes in such
blood measurements as potassium, uric acid, lipids, and glucose.
Beta blockers also can provide metabolic changes. The costs involved in providing extra drugs to counteract these changes, as well
as in additional laboratory tests and clinic visits, largely eliminate
the apparent price advantages of these traditional agents over the
newer drugs.
Equally fierce controversy, therapeutic benefit versus cost, also
has arisen in the frequently encountered area of cholesterol abnormalities for which optimal treatment often requires the use of relatively expensive agents such as the HMG CoA reductase
inhibitors.6" But because of the high cost of this drug class-approximately $1.50 per day-institutions have already claimed that
they realistically cannot afford to provide this type of treatment for
the large numbers of patients who appear to need the treatment.
From the point of view of the individual patient, the daily cost of
providing such treatment is less than that of a pack of cigarettes;
but formulary committees, looking solely at the drug acquisition
components of their own budgets rather than at the big picture of
59

See generally Weber & Laragh, supra note 53, at 149-52.

60 The HMG CoA Reductase Inhibitors are drugs that have been made available

for general use during the past five years. Current examples are pravastatin, lovastatin, and simvastatin. These drugs are able to decrease the manufacture of cholesterol
within the liver. This, in turn, provokes special molecules (scientifically termed "receptors") on the surface of the liver to increase their attraction for certain forms of
cholesterol circulating in the blood. Thus, the liver is stimulated into removing substantial amounts of an undesirable form of cholesterol known as low density lipoprotein (LDL) cholesterol from the blood, thereby decreasing the risk to patients of
damage to critical arteries such as the coronaries which serve the heart.
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long-term health outcomes, are likely to impose restricted access to
this type of treatment.

F

The Role of the Food and Drug Administration

The FDA is a federal regulatory agency that has been guided
by a clear philosophy in deciding which new drugs to approve for
marketing. In essence, the first requirement is that the new drug
demonstrate efficacy that is either clearly superior to a placebo or
is equal to that of other similar agents already available. Second,
the drug must be shown to be safe, or to have adverse effects that
are acceptable within the context of the drug's benefits.
The FDA has rarely, if ever, used cost-effectiveness as a criterion for new drug approval. The agency has based its decisions on
safety and efficacy, and has assumed that physician and patient
judgment, together with market forces, will govern the extent to
which the drug is used. There is now some apprehension that the
FDA may be taking a tougher stand, especially with "me too" drugs
that, although differing slightly in their chemical structure from
already available products, have similar therapeutic properties. It
is also possible that the FDA could be instructed-perhaps along
the lines recommended within the proposed new legislation regarding Medicare prescription benefits6 1-to take cost into account even when considering approval of truly new drug products.
It is clearly important that the future role of the FDA in the drug
approval process be clearly defined. Otherwise, patients again
might have reason to fear that they may be denied access to stateof-the-art treatment. Furthermore, the future role of the FDA in
governing product promotion and education by industry must be
clarified.

G.

Tort Reform

Health care economists, as well as physicians, have claimed for
several years that a major part of health care costs results from
problems with medical liability. The cost of malpractice insurance
has become a substantial part of the expenses of practicing clinicians. 62 Moreover, physicians' perceived need to practice "defen61 See supra note 8 and accompanying text for some insight on Medicare drug
prescriptions.
62 Insurance companies or physicians' cooperatives that deal in selling medical
malpractice insurance are reluctant to publicly publish their tariffs. One of the reasons for this is that they try, as far as possible, to individualize rates for physicians and
to make some estimate of an appropriate premium based on risk. This takes into
account doctors' personal histories in terms of training, formal qualifications, and
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sive medicine," which entails expensive procedures performed
primarily to protect against lawsuits rather than to help patients,
adds yet further to the cost of providing care. Thus, imposing limits on the maximum size of judgments, and discouraging frivolous
legal actions, has become an important issue for those seeking to
change the health care system.
Some of the issues discussed earlier in this section, including
the Health Net case, raise the possibility of an interesting paradox.
It is now not the individual physician who will necessarily be responsible for choosing a patient's treatment, but rather a business
entity that is operating a for-profit health plan. Certainly, the patient must have assurance that powerful and meaningful legal remedies will be available to protect not only against poor professional
judgement, but, perhaps more importantly, against adverse business-dominated decisions. Physicians who value the individualization of patient care, and who put value upon their personal
relationships with patients, might unexpectedly find themselves allied with attorneys in their fight to provide optimal care, including
drugs, for their patients. Despite the enthusiasm of the White
House and of many large health plans for tort reform, members of
the medical profession and, perhaps, the pharmaceutical industry
as well, might wish a delay in such changes.
VI.

INDUSTRY RESPONSES:

BEING CREATIVE IN A

CHANGING ENVIRONMENT

Understandably, there is apprehension within the pharmaceutical industry as it contemplates widespread changes in the health
care system. These concerns exist not only within the industry, for
a marked devaluation of drug industry stocks has served to indicate
that business observers and investors are expressing some caution
over the future prospects of pharmaceuticals. 6" Numerous newspaprevious involvement with malpractice claims. More importantly, the type of specialty
in which a physician is involved is a major determinant. For example, the plan with
which the author is associated in Southern California has premiums that range from
approximately $5000 per year for primary care physicians to approximately $100,000
per year for high-risk surgical specialties and certain types of obstetrical practices.
63 During 1993, drug prices increased only 0.4 percentage points faster than the
consumer price index (CPI) for all items, and much more slowly than the CPI for
medical care. With rapidly escalating research and development costs, the moderation in drug prices has squeezed industry profitability. Pharmaceutical stocks fell by
22% in 1992 and declined at an annual rate of 25% during the first half of 1993,
resulting in a $90 billion loss in market value. Financial Trends in the Pharmaceutical
Industry and ProjectedEffects of Recent FederalLegislation, PHARMACEUTICAL MANUF. ASS'N
(Price Waterhouse), Oct. 21, 1993, at 20.
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per and business magazine articles have pointed out the pressures
on the pharmaceutical industry.6 4 But it should be remembered
that the growth of pharmaceutical companies during the ten or
twelve-year period before 1990 was so extraordinary that the more
recent reductions in the rate of revenue growth, stock values, and
employment could be interpreted, at least in part, as a predictable
correction.
There are a variety of strategies that pharmaceutical companies could use to allow them to survive and grow in the type of
health care environment we are likely to see during the next several years. For simplicity, these approaches can be subdivided into
three main groups: business strategies; physician-based strategies;
and patient-based strategies. It is the approach to the patient, who
now more than ever must be regarded as the true consumer, that
might offer some of the most creative opportunities to ensure both
a viable industry and a high quality of health care.
A.

Business Strategies

In a pharmaceutical marketplace where decisions on drug use
by individual physicians are being at least partly replaced with corporate decisions by HMOs and other health care plans, the pharmaceutical industry clearly must develop methods for marketing
their products to these high volume purchasers. The most simple
competitive approach, of course, is to bid with low prices in order
to obtain formulary selection within major health plans. This type
of activity already represents an important marketing strategy for
most of the major pharmaceutical companies.
B.

The Vertical Integration Approach

Traditionally, the relationship between the pharmaceutical industry and the principal users of their products has been that of a
vendor and a customer. However, as strategies based primarily on
pricing may no longer be adequate in a progressively more competitive setting, alternative approaches are now being contemplated. The acquisition of Medco by Merck, discussed earlier, is
one example of how a major pharmaceutical company has gone
beyond being simply a supplier of pharmaceutical products, and is
now providing services as well as drugs directly within the health
care system.
64 See, e.g., Shawn Tully, The Plots to Keep Drug Prices High, FORTUNE, Dec. 27, 1993,
at 120, 120-24; Doug Bandow, Missing the Mark, PRiVATE PRACTICE, Sept. 1993, at 29;
Robert Goldberg, The Myth of High Drug Costs, WALL ST. J., Sept. 30, 1992, at A16.
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One strategy that pharmaceutical companies might contemplate is to go even beyond the Medco model and form long-term
relationships with major health plans. In essence, pharmaceutical
companies could acquire major equity interests in health plans,
creating a situation in which they can guarantee long-term use of
their products. At least one of the major companies has looked
seriously at creating such an alliance.6 5 In a sense, there is already
a precedent: several of the major health insurance carriers, also
anxious to protect their long-term prospects, have acquired or cre66
ated their own health plans.
A less dramatic strategy than the "pharmaceutical services" or
"ownership" models is the concept of "bundling." This requires
that a large pharmaceutical company, with a broad range of products encompassing most of the common therapeutic areas, makes
an arrangement for its entire product line to be used preferentially
by major health plans. Making its full portfolio available in this
fashion can be helpful to a pharmaceutical company, for by increasing the usage of some of its less popular products, it can then
afford, in essence, to subsidize some of its more popular or expensive products. In practice, the range of necessary drugs required by
a comprehensive health plan is so great that not even the largest
pharmaceutical companies can come close to truly satisfying this
need. However, consortiums of pharmaceutical companies could
bid jointly to acquire comprehensive drug supply contracts from
major plans.
Interestingly, these more complex bundling models may finish
up by being similar in some respects to the Medco operation.
Should these types of business solutions become more widespread
than at present, there must inevitably be some ethical concern
within the medical community. Certainly in a setting where a pharmaceutical manufacturer has as much financial interest in profitable health care delivery at the bedside as in its traditional sales of
drugs, it could be feared that the critical processes of research and
development might be driven by fiscal rather than by scientific and
clinical forces.
65 See American Drug Firms: Kicking the Habit, THE ECONOMIST, Dec. 25, 1993, at 90,
92 (pointing out that the Pfizer Corporation has been considering such an option).
66 Margie Freaney, Aetna Boldly Remaking Itself BALTIMORE Bus. J., Oct. 1, 1993, at
1. This article discusses how Aetna, traditionally one of the major insurance carriers,
has undergone a radical restructuring, and has decided that its future viability lies in
its ability to exert tight cost-control over the health care that is provided under its
aegis. Id. Accordingly, the formation of a tightly controlled HMO is a critical part of
its planning. Id.
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C. Physician Strategies
Much of this article has already discussed the close relationship that traditionally has existed between the pharmaceutical industry and physicians. Obviously, as health plans make business
decisions regarding drug acquisition, this relationship is tending to
become diluted by the interposition of formulary committees,
pharmaceutical consultants, and other intermediaries.
But, ultimately, the physician remains-and for the foreseeable future will continue to remain-the person who will continue
to have decision-making input for drug treatment in individual patients. As detailed in an earlier section of this Article, there has
been a recent tendency for pharmaceutical companies to decrease
their interactions with physicians. Sales calls have been reduced,
and educational activities, either at local hospitals or through major medical societies, have also been reduced.
In an environment where medical decisions are being made
progressively more by individuals trained primarily in business, it
will become very important for physicians to be informed advocates
for drug advances. Research into drugs and their use is a continuous process throughout the lives of drugs. New information is always being obtained, and there is a strong need to keep physicians
aware of developments that can enhance and broaden the use of
therapeutic agents in their patients. Moreover, even though aggressive marketing strategies might bring a particular product onto
a formulary, this does not guarantee that physicians within the plan
will use the drug, or if they use it, that it will be prescribed appropriately. Indeed, the provision of physician educational services,
either informally as at present, or perhaps even on a structured or
contractual basis, is an important obligation for pharmaceutical
companies and a good opportunity to optimize the use of their
products.
D.

The Patient Strategy

In a world where the pharmaceutical industry is being
squeezed by governments, insurers, and health plans, it is critical
that, finally, direct communication with the true consumer, the patient, will open up. Indeed, at present the lay public's understanding of the pharmaceutical industry, and the whole process by which
therapeutic drugs are provided, is so poor that the industry-despite the extraordinary contributions it has made to modern health
care-has become an almost undefended victim of widespread criticism. Long-term prospects for the industry, and thereby for the
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quality of health care, might depend very closely on its ability to
educate the public. The following issues appear especially
appropriate.
1.

Where Do Drugs Come From?

It is likely that only a tiny fraction of the general population
understands the extraordinarily complex, lengthy, and expensive
process of providing new therapeutic products. It is likely that
much of the information discussed earlier concerning the "drug
development pyramid," which is not understood even by most physicians, would certainly surprise most members of the lay public.
There is no real understanding of the concept that much of the
price of drugs is not to make the pills, but to amortize the research
and development costs.
One common misconception is shown in Figure 3. When considering the origins of the most commonly prescribed drugs in this
country, the reality is that over ninety-five percent were developed
by the pharmaceutical industry. The general public, however, has
a completely erroneous perception of this process, and believes
FIGURE

3

.The 100 Most Prescribed Drugs?

Public
Perception
SOURCE: HARRIS POLL 1993 and PMA

PMA
Data
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that the majority of therapeutic breakthroughs have come from research by government or university investigators.6 7 It is unfortunate for medical care overall that this type of misunderstanding
exists; the blame, to be fair, belongs primarily to the pharmaceutical industry itself. Very simply, it has not spoken to its own customers.
2. What Drugs Cost
A further result of poor communication is shown in Figure 4.
Although they are the cornerstone of most therapies, drugs in reality account for only about seven percent of total health care costs. 68
But in the minds of the public, drugs appear to have a far more
dramatic importance, approaching one-third of overall costs. 69
This misconception is not totally surprising. Many patients, even
those with good private insurance plans, are required to pay part
or all of their own drug costs. In many instances, especially for
FIGURE
Percent

4

Drug Costs

55%ol

Drugs as a % of
Public Perception % of Drug Costs
Health Care Costs of Drugs as a % of Paid Out of Pocket
Health Care Costs
SOURCE: HARRIS POLL, 1993 and 1994

67 See Figure 3 for some support for this proposition.
68 See supra note 4.
69 See Figure 4.

1994] MEDICINE AND THE PHARMACEUTICAL INDUSTRY 1323
patients who may be taking multiple drugs for chronic conditions,
these out-of-pocket expenses can often dwarf their other personal
health care expenses. For this reason, anti-industry rhetoric from
Washington falls on receptive ears. Again, education is vital.
3.

What Drugs Do

For many patients, especially the elderly who might simultaneously be affected by such common conditions as hypertension, diabetes, heart disease, or arthritis, it is inevitable and appropriate
that they receive multiple drugs. Although no physician likes to
prescribe more drugs than are necessary, these drug regimens are
needed to prevent strokes, comas, or other complications of diabetes, severe pain, and major cardiac events. The cost of the drugs,
albeit rather startling when a patient is asked to fill prescriptions
for a month's supply of four or five differing medications, is still
trivial when compared with the cost of hospitalization or other major interventions that would be required if the drugs were not used.
Unfortunately, for most lay patients, let alone formulary committees who ought to know better, there is a preoccupation with
drug acquisition costs without an appropriate understanding of the
total financial picture. Beyond education, one approach to lessening the personal financial impact on patients is to encourage expanded use of prescription benefit plans. These approaches,
which are being offered more widely by several insurance carriers,
and are even envisaged to some extent under the new Medicare
rules,7 ° limit out-of-pocket expenses and the total annual personal
cost of drug products. Much or most of the drug costs are, in fact,
then carried by the plan, which presumably has a clear understanding of how wise investment in modern drugs can actually save major expenses in other areas.
4.

Quality of Drug Treatment

In a medical marketplace characterized by competitive health
care plans, patients will be forced to evaluate the differing claims of
rival plans when making choices for themselves or their families.
Several factors might influence these decisions, including cost,
convenience of the plan's physical facilities, or perhaps personal
acquaintance with physicians or other personnel within a particular plan. But because the plans tend to be very complex and have
several attributes that could influence their potential subscribers, it
70 See supra note 8 and accompanying text for a discussion of Medicare rules for
prescription medicines.
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is likely-and highly desirable-that detailed evaluations of the
plans, on a feature by feature basis, be published regularly within
each community by objective observers.7 1
It is critical for the pharmaceutical industry, and other advocates for high quality medical care, to ensure that plans compete
on the basis of quality of their treatment-especially highlighting
the availability of modern drugs-in addition to such other issues
as cost. Choosing one plan over another because it offers a
broader range of state-of-the-art drugs could be a legitimate way for
educated patients to receive the best value for their health care
investment.
VII.

FINAL COMMENT

The pharmaceutical industry has already been impacted by a
widely expressed desire to curtail health care costs. Because the
industry has been perceived as successful and prosperous, it has
been a ready target for those who claim to see excesses in current
health care expenditures. Drugs remain the primary tools for
treating most physical and mental illnesses, and there is legitimate
concern that cost pressures on the pharmaceutical industry could
reduce its incentive to develop innovative new products. The cost
of drug research and development is extraordinarily high, and it is
critical that physicians, health plan administrators, and especially
patients, be made to understand the whole process of making therapeutic products accessible.
This Article has argued that the pharmaceutical industry,
through its support of many aspects of medical research and education, is integral to quality health care. There are a number of
strategies that individual pharmaceutical companies might follow
to preserve their viability and growth in the changing health care
market. But most important of all is a need for pharmaceutical
companies to carefully educate their ultimate consumers-the patients-on the importance of demanding full access to contemporary drug therapy in a health care system dominated increasingly
by the business objectives of health plan managers rather than by
traditional doctor-patient relationships.

71 The type of rating scale used by Consumer Reports to judge products and services
in the general marketplace is a good model for these evaluations.

